Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

19.0%

70 terminated/withdrawn out of 369 trials

Success Rate

72.7%

-13.9% vs industry average

Late-Stage Pipeline

11%

39 trials in Phase 3/4

Results Transparency

48%

89 of 186 completed trials have results

Key Signals

45 recruiting89 with results53 terminated17 withdrawn

Enrollment Performance

Analytics

N/A

138(44.8%)

Phase 2

79(25.6%)

Phase 1

48(15.6%)

Phase 4

21(6.8%)

Phase 3

18(5.8%)

Early Phase 1

4(1.3%)

308Total

N/A(138)

Phase 2(79)

Phase 1(48)

Phase 4(21)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (369)

Showing 20 of 369 trials

NCT07028216Not ApplicableRecruiting

Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method

Role: lead

NCT02190253Completed

Seroprevalence of Hepatitis E in People With an Organ Transplant

Role: collaborator

NCT07540000Phase 4Not Yet Recruiting

The INTERvening for LUNG Health Trial

Role: collaborator

NCT06902623Not ApplicableRecruiting

Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy

Role: lead

NCT06227546Phase 2Active Not Recruiting

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Role: lead

NCT04248257Not ApplicableActive Not Recruiting

Peer Support For Young Adult Women With High Breast Cancer Risk

Role: lead

NCT03964532Phase 1Active Not Recruiting

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Role: lead

NCT05334732Not ApplicableRecruiting

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

Role: collaborator

NCT06554158Not ApplicableRecruiting

De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers

Role: lead

NCT04990102Phase 1Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Role: lead

NCT05479045Phase 2Not Yet Recruiting

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

Role: lead

NCT04499053Phase 2Recruiting

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Role: lead

NCT04488081Phase 2Active Not Recruiting

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Role: collaborator

NCT06295250Not ApplicableRecruiting

ASHA Bangladesh--An Integrated Intervention to Address Poverty and Depression

Role: collaborator

NCT07228000Not ApplicableNot Yet Recruiting

Bundled Cancer Screening and Genetic Services Navigation

Role: lead

NCT05661201Phase 1Recruiting

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Role: lead

NCT07221747Not ApplicableRecruiting

PathToScale: The PERSIST Trial

Role: lead

NCT04091750Phase 2Active Not Recruiting

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Role: lead

NCT07439172Phase 2Not Yet Recruiting

Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.

Role: collaborator

NCT07418905Not ApplicableActive Not Recruiting

Technology-supported Motor Rehabilitation for People With Rett Syndrome

Role: lead